A Novel Tool for Detecting Amyloid Deposits in Systemic Amyloidosis in Vitro and in Vivo

Laboratory Investigation

Volumn 83, Issue 12, 2003, Pages 1751-1759

  Ando, Yukio ^a   Haraoka, Katsuki ^a   Terazaki, Hisayasu ^a   Tanoue, Yutaka ^b   Ishikawa, Kensuke ^c   Katsuragi, Shoichi ^e   Nakamura, Masaaki ^a   Sun, Xuguo ^a   Nakagawa, Kazuko ^b   Sasamoto, Kazumi ^f   Takesako, Kazuhiro ^f   Ishizaki, Takashi ^b   Sasaki, Yutaka ^a   Doh Ura, Katsumi ^d  

^a KUMAMOTO UNIV SCHOOL OF MEDICINE   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

^c KYUSHU UNIVERSITY   (Japan)

^d TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e Kikuchi National Hospital Division of Clinical Research   (Japan)

^f Dojin Chemical Company   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1 BROMO 2,5 BIS(3 HYDROXYCARBONYL 4 HYDROXY)STYRYLBENZENE; AMYLOID; AMYLOID A PROTEIN; BENZENE DERIVATIVE; CONGO RED; PREALBUMIN; UNCLASSIFIED DRUG;

ADULT; AMYLOIDOSIS; ARTICLE; AUTOPSY; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; ELECTRON MICROSCOPY; FAMILIAL AMYLOID POLYNEUROPATHY; FAMILIAL DISEASE; FEMALE; HISTOCHEMISTRY; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; IN VITRO STUDY; IN VIVO STUDY; INTERMETHOD COMPARISON; MALE; MOLECULAR GENETICS; PRION DISEASE; PRIORITY JOURNAL; PROTEIN DETERMINATION; RELIABILITY;

ADULT; AMYLOID; AMYLOIDOSIS; ANIMALS; CONGO RED; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICE; MIDDLE AGED; PREALBUMIN; STAINING AND LABELING; STYRENES;

EID: 9144262344     PISSN: 00236837     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.LAB.0000101701.87433.C5     Document Type: Article

References (52)

1. Ando Y, Ando E, Ohlsson PI, Olofsson Å, Sandgren O, Suhr O, Terazaki H, Obayashi K, Lundgren E, Ando M, and Negi A (1999). Analysis of transthyretin (TTR) forms of amyloid fibrils from vitreous samples in familial amyloidotic polyneuropathy (Met30). Amyloid 6:119-123.
2. Ando Y, Nakamura M, Kai H, Katsuragi S, Terazaki H, Nozawan T, Okuda T, Misumi S, Matsunaga N, Tajiri T, Shoji S, Yamashita T, Haraoka K, Obayashi K, Matsumoto K, Ando M, and Uchino M (2002). A novel localized amyloidosis associated with lactoferrin in the cornea. Lab Invest 82:757-766.
3. Benditt EP, Eriksen N, and Berglund C (1970). Congo red dichroism with dispersed amyloid fibrils, an extrinsic cotton effect. Proc Natl Acad Sci USA 66:1044-1051.
4. Benson MD (1995). Amyloidosis. In: Scriver CR, Beaudet AK, Sly WS, and Valle D, editors. The metabolic and molecular bases of inherited disease. New York: McGraw-Hill, 4159-4191.
5. Benson MD, Liepnieks J, Uemichi T, Wheeler G, and Correa R (1993). Hereditary renal amyloidosis associated with a mutant fibrinogen-chain. Nat Genet 3:252-255.
6. Benson MD and Uemichi T (1996). Transthyretin amyloidosis. Amyloid 3:44-56.
7. Bi W, Hayes RB, Feng P, Qi Y, You X, Zhen J, Zhang M, Qu B, Fu Z, Chen M, Co Chien HT, and Blot WJ (1992). Mortality and incidence of bladder cancer in benzidine-exposed workers in China. Am J Ind Med 21:481-489.
8. Case RAM, Hosker MW, McDonald DB, and Pearson JT (1954). Tumors of the urinary bladder in workmen engaged in the manufacture and use of certain dyestuff intermediates in the British chemical industry. Br J Ind Med 11:75-104.
9. 99mTc-MAMA-chrysamine G, a probe for beta-amyloid protein of Alzheimer's disease. Eur J Nucl Med 26:1392-1399.
10. 99mTc-MAMA-chrysamine G as an in vivo probe for amyloidosis. Amyloid 8:202-214.
11. 99Tcm-labelled N2S2 conjugates of chrysamine G for amyloid deposits of systemic amyloidosis. Nucl Med Commun 22:553-558.
12. Giger M, Baumgartner HR, and Zbinden G (1974). Toxicological effects of Evans blue and Congo red on blood platelets. Agents Actions 4:173-180.
13. Giger M and Zbinden G (1974). Significance of the albumin concentration for the toxic effect of Evans blue and Congo red on thrombocytes. Schweiz Med Wochenschr 104:1376-1377.
14. Goldberg ME, Rudolph R, and Jaenicke R (1991). A kinetic study of the competition between renaturation and aggregation during the refolding of denatured-reduced 197-egg white lysozyme. Biochemistry 30:2790-2797.
15. Guy CD and Jones CK (2001). Abdominal fat pad aspiration biopsy for tissue confirmation of systemic amyloidosis: Specificity, positive predictive value, and diagnostic pitfalls. Diagn Cytopathol 24:181-186.
16. Hachulla E, Deveaux M, Duquesnoy B, and Marchandise X (1994). Scintigraphy using amyloid P component labelled with iodine 123: A new method of evaluation of amyloidosis. Presse Med 23:348.
17. Hachulla E, Maulin L, Deveaux M, Facon T, Bletry O, Vanhille P, Wechsler B, Godeau P, Levesque H, Hatron PY, Huglo D, Devulder B, and Marchandise X (1996). Prospective and serial study of primary amyloidosis with serum amyloid P component scintigraphy: From diagnosis to prognosis. Am J Med 101:77-87.
18. 123I-labeled serum amyloid P component. N Engl J Med 323:508-513.
19. Hoshii Y, Kawano H, Cui D, Takeda T, Gondo T, Takahashi M, Kogishi K, Higuchi K, and Ishihara T (1997). Amyloid A protein amyloidosis induced in apolipoprotein-E-deficient mice. Am J Pathol 151:911-917.
20. Ikeda S, Nakazato M, Ando Y, and Sobue G (2002). Familial transthyretin-type amyloid polyneuropathy in Japan: Clinical and genetic heterogeneity. Neurology 58:1001-1007.
21. Ishihara T, Nagasawa T, Yokota T, Gondo T, Takahashi M, and Uchino F (1989). Amyloid protein of vessels in leptomeninges, cortices, choroid plexuses, and pituitary glands from patients with systemic amyloidosis. Hum Pathol 20:891-895.
22. Kaplan B, Vidal R, Kumar A, Ghiso J, and Gallo G (1999). Immunochemical microanalysis of amyloid proteins in fine-needle aspirates of abdominal fat. Am J Clin Pathol 112:403-407.
23. Kennelly JC, Shaw A, and Martin CN (1984). Reduction to benzidine is not necessary for the covalent binding of a benzidine azodye to rat liver DNA. Toxicology 32:315-324.
24. Klunk WE, Debnath ML, Koros AM, and Pettegrew JW (1998). Chrysamine-G, a lipophilic analogue of Congo red, inhibits A beta-induced toxicity in PC12 cells. Life Sci 63:1807-1814.
25. Klunk WE, Debnath ML, and Pettegrew JW (1994). Development of small molecule probes for the beta-amyloid protein of Alzheimer's disease. Neurobiol Aging 15:691-698.
26. Klunk WE, Debnath ML, and Pettegrew JW (1995). Chrysamine-G binding to Alzheimer and control brain: Autopsy study of a new amyloid probe. Neurobiol Aging 16:541-548.
27. LeVine H 3rd (1993). Thioflavine T interaction with synthetic Alzheimer's disease beta-amyloid peptides: Detection of amyloid aggregation in solution. Protein Sci 2:404-410.
28. Masouye I (1997). Diagnostic screening of systemic amyloidosis by abdominal fat aspiration: An analysis of 100 cases. Am J Dermatopathol 19:41-45.
29. Matsuno H, Niikura K, and Okahata Y (2001). Direct monitoring kinetic studies of DNA polymerase reactions on a DNA-immobilized quartz-crystal microbalance. Chemistry 7:3305-3312.
30. Moran JK (1999). Technetium-99m-EC and other potential new agents in renal nuclear medicine. Semin Nucl Med 29:91-101.
31. Naiki H, Higuchi K, Hosokawa M, and Takeda T (1989). Fluorometric determination of amyloid fibrils in vitro using the fluorescent dye, thioflavin T1. Anal Biochem 177:244-249.
32. Okahata Y, Niikura K, Sugiura Y, Sawada M, and Morii T (1998). Kinetic studies of sequence-specific binding of GCN4-bZIP peptides to DNA strands immobilized on a 27-MHz quartz-crystal microbalance. Biochemistry 37:5666-5672.
33. Pepys MB, Hawkins PN, Booth DR, Vigushin DM, Tennent GA, Soutar AK, Totty N, Nguyen O, Blake CC, Terry CJ, Feest TG, Zalin AM, and Hsuan JJ (1993). Human lysozyme gene mutations cause hereditary systemic amyloidosis. Nature 362:553-557.
34. Puchtler H and Sweat F (1965). Congo red as a stain for fluorescence microscopy of amyloid. J Histochem Cytochem 13:693-694.
35. 99mTc-DPD scintigraphy in transthyretin-related familial amyloidotic polyneuropathy. Eur J Nucl Med 29:376-379.
36. Rydh A, Suhr O, Hietala SO, Ahlstrom KR, Pepys MB, and Hawkins PN (1998). Serum amyloid P component scintigraphy in familial amyloid polyneuropathy: Regression of visceral amyloid following liver transplantation. Eur J Nucl Med 25:709-713.
37. Saile R, Deveaux M, Hachulla E, Descamps J, Duquesnoy B, and Marchandise X (1993). Iodine-123-labelled serum amyloid P component scintigraphy in amyloidosis. Eur J Nucl Med 20:130-137.
38. Saraiva MJ (2001). Transthyretin mutations in hyperthyroxinemia and amyloid diseases. Hum Mutat 17:493-503.
39. Sauerbrey G (1959). Verwendung von Schwingquarzed zur Wagung dunner Schichten und zur Mikrowagung. Z Phys Vlo 155:206.
40. Schmidt ML, Schuck T, Sheridan S, Kung MP, Kung H, Zhuang ZP, Bergeron C, Lamarche JS, Skovronsky D, Giasson BI, Lee VM, and Trojanowski JQ (2001). The fluorescent Congo red derivative, (trans, trans)-1-bromo-2,5-bis-(3-hydroxycarbonyl-4-hydroxy)styrylbenzene (BSB), labels diverse beta-pleated sheet structures in postmortem human neurodegenerative disease brains. Am J Pathol 159:937-943.
41. Sipe JD and Cohen AS (2000). Review: History of the amyloid fibril. J Struct Biol 130:88-98.
42. Skovronsky DM, Zhang B, Kung MP, Kung HF, Trojanowski JQ, and Lee VM (2000). In vivo detection of amyloid plaques in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 97:7609-7614.
43. Soutar AK, Hawkins PN, Vigushin DM, Tennent GA, Booth SE, Hutton T, Nguyen O, Totty NF, Feest TG, Hsuan JJ, and Pepys MB (1992). Apolipoprotein AI mutation Arg-60 causes autosomal dominant amyloidosis. Proc Natl Acad Sci USA 89:7389-7393.
44. Tan SY and Pepys MB (1994). Amyloidosis. Histopathology 25:403-414.
45. Tan SY, Pepys MB, and Hawkins PN (1995). Treatment of amyloidosis. Am J Kidney Dis 26:267-285.
46. Terazaki H, Ando Y, Misumi S, Nakamura M, Ando E, Matsunaga N, Shoji S, Okuyama M, Ideta H, Nakagawa K, Ishizaki T, Ando M, and Saraiva MJ (1999). A novel compound heterozygote (FAP ATTR Arg104His/ATTR Val30Met) with high serum transthyretin (TTR) and retinol binding protein (RBP) levels. Biochem Biophys Res Commun 264:365-370.
47. Westermark GT, Johnson KH, and Westermark P (1999). Staining methods for identification of amyloid in tissue. Methods Enzymol 306:3-25.
48. Westermark GT and Westermark P (2000). Endocrine amyloid: A subject of increasing interest for the next century. Amyloid 71:19-22.
49. Westermark P, Benson MD, Buxbaum JN, Cohen AS, Frangione B, Ikeda S, Masters CL, Merlini G, Saraiva MJ, and Sipe JD (2002). Amyloid fibril protein nomenclature-2002. Amyloid 9:197-200.
50. Zenser TV, Lakshmi VM, and Davis BB (1998). N-glucuronidation of benzidine and its metabolites: Role in bladder cancer. Drug Metab Dispos 26:856-859.
51. Zhuang ZP, Kung MP, Hou C, Plossl K, Skovronsky D, Gur TL, Trojanowski JQ, Lee VM, and Kung HF (2001a). IBOX(2-(4′ -dimethylaminophenyl)-6-iodobenzoxazole): A ligand for imaging amyloid plaques in the brain. Nucl Med Biol 28:887-894.
52. Zhuang ZP, Kung MP, Hou C, Skovronsky DM, Gur TL, Plossl K, Trojanowski JQ, Lee VM, and Kung HF (2001b). Radioiodinated styrylbenzenes and thioflavins as probes for amyloid aggregates. J Med Chem 44:1905-1914.